Ethics
The survey was notified to the Internal Review Board of the University Hospital “AOUP, P. Giaccone”, Palermo (approval code 138/2020). The current study complies with the Declaration of Helsinki.
Acknowledgments
The authors are grateful to patients for their availability.
Author Contributions
All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the letter or revising it critically for important intellectual content; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.
Disclosure
MN acted as consultant for Bayer, BIOFVIIIx, Novonordisk, and Amgen and received speaker fees from: Kedrion, Octapharma, Baxalta, CSL Behring, Novonordisk, and Bayer. SS acted as consultant for Bayer, BIOFVIIx, and Novonordisk and received speaker fees from: Kedrion, Octapharma, Amgen, Baxalta, CSL Behring, Novonordisk, Bayer, and Novartis. All other authors have no relevant conflicts of interest to declare.